Sp464
DIET AND MICROBIOME-BASED THERAPIES FOR IBD - WHAT ARE THE DATA?
Date
May 7, 2023
Explore related products in the following collection:
Society: AGA
In the last five years, there have been three distinct small molecules that have been approved for the management of ulcerative colitis. This session will review the efficacy, safety and practical applications for use of these agents in the management of ulcerative colitis and examine their role in Crohn’s disease. . It will also examine the current role of non-targeted small molecules (thiopurines and methotrexate), diet, and microbiome-directed therapies in the treatment of IBD.
In the last five years, there have been three distinct small molecules that have been approved for the management of ulcerative colitis. This session will review the efficacy, safety and practical applications for use of these agents in the management of ulcerative colitis and examine their role in Crohn’s disease. . It will also examine the current role of non-targeted small molecules (thiopurines and methotrexate), diet, and microbiome-directed therapies in the treatment of IBD.
Presenter
Massachusetts General Hospital
Tracks
Related Products
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
GUT MICROBIAL METABOLISM OF 5-ASA IS PROSPECTIVELY ASSOCIATED WITH TREATMENT FAILURE
The microbiome plays a central role in intestinal inflammation in IBD. It is influenced by environmental factors included diet…
THE SULFUR MICROBIAL DIET AND RISK OF INFLAMMATORY BOWEL DISEASE
BACKGROUND The gut microbiome is central to Crohn’s disease (CD) pathogenesis but the relative contribution of different environmental factors to disease compositional variation is unknown…
PANEL DISCUSSION
In the last five years, there have been three distinct small molecules that have been approved for the management of ulcerative colitis…
